Programme

The time in the Agenda is specified by local time.

Download the programme here

September 22

13:00 Registration
13:30 Plenary1

Prof. Dr. Vladimir Gevorgyan, University of Texas at Dallas, USA

New Heterocyclization and C–H Functionalization Methods

Session1

Chemistry of heterocyclic compounds

Session3

Drug delivery
14:20

Prof. Dr. Dmitriy Volochnyuk, Institute of Organic Chemistry NAS of Ukraine, UA

Amino Acids Derived Diazoketones – Shelf Stable Reagents for Heterocyclizations

14:20

Prof.  Dr. Tambet Teesalu, University of Tartu, EE

Precision Targeting of Drugs and Nanoparticles with Homing Peptides

14:50

Prof. Dr. Sergey Ryabukhin, TS National University of Kyiv & Enamine, UA

MedChem-Relevant gem-Difluorocycloalkane Building Blocks and Their Impact on Physicochemical Properties

14:50

Prof. Dr. Valentín Ceña, Universidad de Castilla-La Mancha, ES

Nanomedicine for Glioblastoma Therapy

15:20

Prof. Dr. Till Opatz, Johannes Gutenberg-University Mainz, DE

Chemical Contributions to Fighting and Preventing Prevalent Diseases

 

Dr. Antons Sizovs, Latvian Institute of Organic Synthesis, LV

Pharmacokinetics, Biodistribution and Passive Tumor Accumulation of Non-opsonizing Nanoparticles

15:50-16:20 Coffee break

Session2

Advanced technologies in Drug Discovery    
16:20

Dr. Sigitas Mikutis, University of Cambridge, UK

Small Molecule Targeted RNA Degraders – RNA Modifications, SARS-CoV-2 and Beyond

   
16:50

Prof. Dr. Igor Komarov, TS National University of Kyiv & Enamine, UA

Diarylethenes as Promising Drug Candidates for Photopharmacology

17:20

Dr. Ross McLennan, University of Dundee, Scotland, UK

Rational Design of a SMARCA2 Selective and Orally Bioavailable VHL-recruiting PROTAC

18:00 Posters up
19:00 Welcome Reception, Restaurant at the Conference venue

September 23

08:00 Registration
08:30 Opening by the State Secretary for the Ministry of Education and Science Līga Lejiņa
08:45 Plenary2

Prof. Dr. Christopher Schofield, University of Oxford, UK

Adventures with Oxygen - from basic science to new drugs

09:30 Plenary3

Prof. Dr. Rolf Müller, Helmholtz-Insititute for Pharmaceutical Research, DE

Approaches Towards Innovative Antibiotics from Microbes

10:15-10:45 Coffee break

Session4

Antiinfectives

Session7

Metabolism
10:45

Prof. Dr. Fredrik Björkling, University of Copenhagen, DK

Activity-enhanced Antimicrobial Peptides

10:45

Prof. Dr. Ilze Konrāde, Rīga Stradiņš University, LV

Cardiometabolic Effects of New Classes of Antidiabetic Agents: a way back to cardiomyocytes

11:15

Dr. Jürgen Brem, Janssen: Pharmaceutical Companies of Johnson & Johnson, BE

Industry Academia Collaboration in AMR R&D: Does it Take Two to Tango?

11:15

Prof. Dr. Lisa Chakrabarti, University of Nottingham, UK

Testing Repurposed Drugs for Neurodegeneration via Mitochondrial Profiling

11:45

Prof. Dr. Paul Finn, Oxford Drug Design, UK

Discovery of Potent Gram-negative Antibacterials Targeting Leucyl-tRNA Synthetase

11:45

Prof. Dr. Steen Larsen, University of Copenhagen, DK

Effects of Exercise on Energy Metabolism – Focus on Mitochondrial Adaptations

12:15-13:30 Lunch

Session5

Anticancer

Session8

CNS
13:30

Prof. Dr. Jean-Yves Winum, University of Montpellier, FR

Multivalent Approach to Targeting Carbonic Anhydrases

13:30

Prof. Dr. Asla Pitkänen, University of Eastern Finland, FI

Systems Biology-Derived Network Treatments for Traumatic Brain Injury and Post-Traumatic Epilepsy - Lessons Learned

14:00

Prof. Dr. Alessio Nocentini, University of Florence, IT

Multi-targeted Chemotherapeutics Hitting G-quadruplex Foldings and Cancer-related Human Carbonic Anhydrases

14:00

Prof. Dr. Jens Pahnke, University of Oslo, NO

ABC Transporter Blood-brain Barrier Function in Neurodegenerative and Neuroinflammatory Diseases – From Basic Research to Treatment

14:30

Prof. Dr. Michael  Gütschow, University of Bonn, DE

Redirecting the Peptide Cleavage: Novel Cathepsin B Inhibitors with Inversely Oriented Warheads

14:30

Prof. Dr. Sven M. Stefan, University of Oslo, NO

Exploring Uncharted Pharmacological Space to Uncover Drug Targets of the Future

15:00

Dr. Pavel Arsenyan, Latvian Institute of Organic Synthesis, LV

Selenium in Drug Discovery: A Blessing and a Curse

15:00

Dr. Līga Zvejniece, Latvian Institute of Organic Synthesis, LV

Metabolomic Signature of Sigma-1 receptor Knock-out Mice

15:30-16:00 Poster session & Coffee break

Session6

Fragment-based drug discovery

Session9

Natural compounds

16:00

Dr. Emilio Parisini, Latvian Institute of Organic Synthesis, LV

Towards the Development of Selective Modulators of Cadherin-mediated cell-cell Adhesion

16:00

Prof. Dr. Nina Hermans, University of Antwerp, BE

Bioavailability and Biotransformation of Polyphenolic Compounds:  Does the Gut Microbiome Play a Lead Role?

16:30

Dr. Daren Fearon, Diamond Light Source Ltd, UK

From Crystallographic Fragment Screen to Preclinical Candidates: Open Science Discovery of New Antivirals

16:30

Ilona Vanaga, University of Latvia, LV

Ancient Survivors - Conifer Polyprenol Studies for Modern Applications

17:00

Prof. Dr. Amedeo Caflisch, University of Zurich, CH

Structure-based Optimization of an Anticancer Compound

17:00

Dr. Inga Sīle, Latvian Institute of Organic Synthesis, LV

Medicinal Plants in Latvia: Traditional Knowledge and Future Perspectives

17:30-18:30 Poster session & Coffee break Latvian Society of Pharmacology meeting
21:00 Social event - Piano quartet "Quadra" concert, Mazā Ģilde, Amatu street 5

September 24

08:30 Plenary4

Prof. Dr. David Crich, University of Georgia, USA

Hydroxalogs

09:15 Plenary5

Dr. David Rees, Astex Pharmaceuticals, UK 

Medicines for Millions of Patients

10:00-10:30 Coffee break

Session9

Natural product synthesis Session11 Structural biology for drug discovery
10:30
 

Prof. Dr. Bengt Erik Haug, University of Bergen, NO

Synthesis of Bioactive Marine Natural Products

10:30

Prof. Dr. Pau Gorostiza, Institute for Bioengineering of Catalonia, ES

Structure-based Design of Photoswitchable Ligands Targeting Enzymes and Receptors

11:15

Prof. Dr. Edgars Sūna, Latvian Institute of Organic Synthesis, LV

Anti-cancer hit from natural product: from total synthesis to drug discovery

11:00

Prof. Dr. Marko Hyvonen, University of Cambridge, UK

Development of Orthosteric Inhibitors of RAD51:BRCA2 Interaction

11:30

Prof. Dr. Martin Hällberg, Karolinska Institute, SE

Structural Virology for Drug Design

12:00-13:15 Lunch
13:15 Plenary6

Prof. Dr. Jieping Zhu, EPFL, CH

Catalytic Enantioselective 1,2-Rearrangement

14:00 Wrap-up